Neurocrine Biosciences, Inc.
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of the earliest event reported): July 17, 2006
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other
jurisdiction of
incorporation or
organization)
|
|
0-22705
(Commission File
Number)
|
|
33-0525145
(IRS Employer Identification
No.) |
| |
|
|
| 12790 El Camino Real, San Diego, CA
|
|
92130 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 617-7600
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2 (b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4 (c)) |
TABLE OF CONTENTS
ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION.
On
July 17, 2006, Neurocrine Biosciences, Inc. announced its
financial results for the six months and quarter ended June 30, 2006. The full text of the press release issued in connection with the
announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2. of Form 8-K, the information in this Current
Report of Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, (“Exchange Act”) or otherwise subject to the
liability of that section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(c) EXHIBITS. The following exhibit is filed herewith:
| |
|
|
| Exhibit |
|
|
| Number |
|
Description of Exhibit |
99.1
|
|
Press Release dated July 17, 2006 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
|
|
|
|
| Dated: July 17, 2006 |
NEUROCRINE BIOSCIENCES, INC.
|
|
| |
/s/ PAUL W. HAWRAN
|
|
| |
Paul W. Hawran |
|
| |
Executive Vice President
and Chief Financial Officer |
|
| |